Research Use Only. No established standalone human dose for KPV. Physician practice use is primarily in blended preparations with BPC-157/TB-500/GHK. Not FDA-approved.
KPV Protocol Reference
Physician practice blend context, anti-inflammatory application, and recovery stack pairing.
Sourced Protocol Frameworks
Source: Physician Practice Literature (blend context)Protocol philosophy: No established standalone human dose. KPV is most appropriately understood as a blend component — combined with BPC-157, TB-500, and/or GHK in physician practice compounding. Blend amounts are product-specific, not a universal standard.
NOTENo established standalone human dose for KPV. Primary practice use is in physician-compounded blends alongside BPC-157/TB-500/GHK.
BLENDSome clinic blends provide fixed KPV amounts alongside other peptides — these are blend-specific, not standalone human standards. The blend dose is what matters in this context.
Reconstitution Reference
No Established Standalone Standard — Blend Context
STANDALONE DOSE
Not established in humans
BLEND CONTEXT
Fixed amounts in clinic-specific blends
DILUENT
BAC water when compounded standalone
STORAGE
Refrigerated 4°C
⚠ No universal reconstitution standard exists for standalone KPV. Blend-specific preparations are formulated by the compounding source.
Pairing & Sequencing
| Compound | Relationship | Sequencing |
|---|---|---|
| BPC-157 | Primary recovery companion | Standard blend combination |
| TB-500 | Anti-inflammatory / repair | Standard blend combination |
| GHK | Collagen/connective tissue | Extended blend combination |
Evidence Status
| Category | Status |
|---|---|
| Overall | Limited human evidence / practice-based |
| Standalone data | Essentially none in humans |
| Blend use | Common in physician practice compounding |
| WADA status | Not prohibited |
Source KPV at Forge Scientific
Third-party tested, HPLC + Mass Spec verified, lot-specific COA. Ships same day — Fort Worth, TX.